Immunicum to trial Bavencio combo

16 November 2018

Swedish biotech Immunicum (STO: IMMU) has announced a collaboration to test its lead product, ilixadencel, an off-the-shelf cell-based cancer immune primer, alongside the anti-PD-L1 monoclonal antibody, Bavencio (avelumab).

Immunicum will initiate the Phase Ib/II study imminently and will be responsible for running the trial, which will test the combination in advanced head and neck cancer and gastric adenocarcinoma. The company will retain all commercial rights to ilixadencel.

Bavencio is being developed under a strategic alliance between Germany’s Merck KGaA (MRK: DE) and US pharma giant Pfizer (NYSE: PFE). It has received accelerated approval in the USA for metastatic Merkel cell carcinoma and for previously-treated patients with locally advanced or metastatic urothelial carcinoma, and is under further clinical evaluation across a range of tumor types.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK